Credo settles Marvell's patent fight with no claim decided as its stock sits 57% below June's high
The deal ends Marvell's USPTO challenge to the patent behind Credo's AI cable business, with no claim decided and terms secret. That clears a legal tail for CRDO holders; the competition question that has halved the stock since June still gets decided on December 1.
Richard Tangthree-minute read
Credo−0.94% — Credo, down 0.94 percent today settled its patent fight with Marvell−2.64% — Marvell, down 2.64 percent today after the close on November 17, 2026, and the relief is aimed at the wrong risk 1. The agreement covers the two companies' patent rights in active electrical cables, the copper links that carry traffic between AI servers, and retires Marvell's pending challenges to Credo's patents at the U.S. Patent and Trademark Office; the terms are confidential 1. That removes a tail risk. It does not restore a moat, because the moat was never going to be decided at the patent office.
The settlement leaves the patent untested
Marvell filed those challenges in August 2025, among them an inter partes review, the patent office's procedure for asking whether a patent should have been granted, aimed at Credo's U.S 2. Patent No. 11,012,252 2. Settled, the review ends with no claim adjudicated: whether the patent would have survived stays unknown, and any money that moved stays hidden 2. Investors paid for the certainty anyway, lifting Credo about 2% after hours 2. The stock had already closed at $123.95 3.
The market is pricing competition, not litigation
Active electrical cables drove more than 90% of Credo's revenue growth last quarter 4. MaxLinear's−3.91% — MaxLinear, down 3.91 percent today chief executive put Credo's share of that market at 93% in October 4. He also said his company will take 20% to 30% of the next, 1.6-terabit generation, whose volume arrives in 2028, Credo's fiscal 2028 4.
That position was earned by shipping qualified cables into five hyperscaler platforms, not by litigating 5. Four customers were 84% of last quarter's revenue 4. The stock is down 57% from its June high, and the bulls have lowered the bar: TD Cowen cut its target from $300 to $175 on November 16, keeping its buy 46.
Credo's quarterly revenue has grown nearly eightfold, to $479 million
Data
| Revenue | |
|---|---|
| Q1 '24 | $60.78M |
| Q2 '24 | $59.71M |
| Q3 '24 | $72.03M |
| Q4 '24 | $135M |
| Q1 '25 | $170.03M |
| Q2 '25 | $223.07M |
| Q3 '25 | $268.03M |
| Q4 '25 | $407.01M |
| Q1 '26 | $437M |
| Q2 '26 | $479M |
Marvell settled copper while betting against it
Two weeks before settling, Marvell agreed to buy Lumentum−1.41% — Lumentum, down 1.41 percent today in an all-stock deal valuing the company at $115 billion, and its own announcement names the physical limits of copper as what pushes AI infrastructure toward optics 7. Credo's hedge is the same bet at its own scale: management targets more than $600 million of optical revenue this fiscal year 4.
The second business was bought with $679 million of cash for the photonics startup DustPhotonics 5. The dated test is the fiscal Q2 report on December 1, 2026 1, with the year's growth target needing roughly $1.46 billion of second-half revenue 4. Dollars on optics make the settlement one clean item in a widening story. No dollars, and it was one day of relief on a stock whose problem is timing.
Credo's year-over-year revenue growth has fallen for four quarters straight, from 274% to 115%
Data
| Revenue growth | |
|---|---|
| Q3 '24 | 63.6% |
| Q4 '24 | 154.4% |
| Q1 '25 | 179.7% |
| Q2 '25 | 273.6% |
| Q3 '25 | 272.1% |
| Q4 '25 | 201.5% |
| Q1 '26 | 157% |
| Q2 '26 | 114.7% |
The patent office was never going to decide who wires the next generation of AI clusters. That is decided in 1.6T orders 4 and in whether optics becomes Credo's second business, and the first answers arrive on December 1 1.
Get Chips by email, free
How AI demand is reshaping chipmakers, memory and the fabs behind them. In our daily email, every weekday.






Reader comments
0 comments